ABSTRACT. Pasteurella multocida is a Gram-negative bacterium known to infect a wide range of domestic and wild animals. The increasing incidence of P. multocida isolated from cases of fowl cholera and hemorrhagic septicemia has led to a renewed interest in this pathogen as well as in the development of vaccines. In this study, PCR primers were designed to amplify the fragment of plpB gene from P. multocida FC-Pakchong (A:1). The purified PCR product of plpB gene consisting of 831 base pairs was inserted into the pGEX-5X-1 plasmid, which expressed the GST protein, and then transformed into E. coli. The purified fusion GST-PlpB protein showed a major band of about 63 kDa on SDS-PAGE gel. After enzyme cleavage, the recombinant PlpB protein appeared at the estimated size of 36 kDa. The recombinant GST-PlpB protein was tested for the toxicity in vivo. The results showed no toxicity in mice at the highest tested concentration of the protein. Moreover, the immunoprotective property of the recombinant GST-PlpB protein was determined in mice after subcutaneous immunization and challenge with an approximate dose of 50-100 LD 50 of P. multocida serotype A:1 and A:3,4. It was demonstrated that this subunit vaccine provided 20-30% survival rate after subcutaneous immunization and challenge with an approximate dose of 50-100 LD 50 of P. multocida serotype A:1 and A:3,4 whereas all of the non-immunized mice died from P. multocida infection. In conclusion, our data indicated that the PlpB protein may not be an appropriate target as a candidate subunit vaccine for P. multocida infection.
Pasteurella multocida is a ubiquitous animal pathogen that is associated with a variety of diseases including hemorrhagic septicemia in cattle, atrophic rhinitis in swine, and fowl cholera in wild and domestic birds. P. multocida strains can be separated into serogroup A, B, D, E and F based on the antigenicity of their capsules and serotypes 1 to 16 based on lipopolysaccharide antigens [9, 10] . This bacterium is Gram-negative, and occurs singly, or in pairs, or short chains. Bipolar staining may be seen and capsules may be present. Pasteurella species are non-motile, facultative anaerobes.
The capsular serogroup is generally related to pathogenicity with hemorrhagic septicemia strains belonging to serogroup B or E and the majority of fowl cholera strains belonging to serogroup A [13] . Fowl cholera is a common avian disease, which may affect all types of birds throughout the world [7] . Encapsulated strains of P. multocida serogroup A and somatic serotypes 1, 3 and 4 are recognized as the primary cause of fowl cholera [8] . Among commercially raised birds, turkeys and Japanese quails are particularly susceptible. Subclinical infections apparently do not exist in normal flocks, but normal-appearing birds that have survived outbreaks of the disease frequently are infected and may serve as carriers.
The increasing incidence of P. multocida isolation from cases of hemorrhagic septicemia and fowl cholera in most parts of the world has led to a renewed interest in this pathogen as well as in the development of vaccines for prevention of these infections. Current P. multocida vaccines contain either inactivated bacteria or live attenuated bacteria. Heat killed vaccine (bacterins) are expensive and must be repeatedly injected. Additionally, bacterins often cause severe tissue reactions and give very limited protection against heterologous serotypes [6] . Attenuated live vaccines can provide limited heterologous protection, but sometimes induce the disease. Rhoades and Rimler have reported that outer membrane protein preparations from in vivo grown P. multocida were able to protect only against the homologous serotype [7] . The 39-kDa antigens of both in vivo and in vitro grown P. multocida were purified by SDS-PAGE and electroeluted from a hydroxyl apatite chromatography column. The purified antigens of various chromatographic fractions obtained from P. multocida can induce active immune cross protection in turkeys, and sera from these turkeys passively cross protected naive poultry [10] . The identity of the 39-kDa protein was determined from the molecular masses of tryptic peptides of Pasteurella PlpB, as listed in the National Center for Biotechnology Information database for P. multocida [12] .
In the present study, the plpB gene of P. multocida FCPakchong serotype A:1 was cloned and expressed in Escherichia coli. Conditions for expression and purification of the recombinant protein were studied. Furthermore, the recombinant protein was investigated for toxicity and immunoprotective activity relative to the possibility of its development as a subunit vaccine.
MATERIALS AND METHODS
Bacterial strains: P. multocida FC-Pakchong (A:1) was kindly provided by the Bureau of Veterinary Biologics (BVB, Department of Livestock Development, Thailand) and other P. multocida strains were provided by National Institute of Animal Health, Thailand. All strains were cultured at 37C in brain heart infusion (BHI) or tryptic soy broth (TSB). E. coli DH5 was the host for cloning experiment and was cultured at 37C in Luria-Bertani broth (LB).
Media were supplemented with 100 g/ml of ampicillin to maintain plasmid selection.
Recombinant DNA techniques: DNA restriction enzymes and T4 DNA ligase were purchased from New England Biolabs and used as recommended by the supplier. Chromosomal DNA isolation of P. multocida used as template for polymerase chain reaction (PCR) was prepared by using QIAamp ® DNA Mini Kit (Qiagen, Germany) according to the manufacturer's instructions. To construct the recombinant plasmid used for expression, PCR primers were used to generate recognition sites of restriction enzyme BamHI and EcoRI at the 5' and 3' end. Primer plpB5 (5'-TT GGA TCC CTA TGA AAT TAA CAA AAC T-3') and plpBe (5'-GAA TTC TTA CCA ACC TTT AAC TAC A-3') were used to amplify the coding sequence of plpB gene. PCR was performed with the following conditions: initial denaturation at 94C for 3 min, followed by 30 cycles of denaturation at 94C for 1 min, annealing at 48C for 1 min, extension at 72C for 1 min and a final extension at 72C for 10 min. The PCR product was then cloned into pGEX-5X-1. The pGEX-5X-1 vector was also digested with BamHI and EcoRI, then ligated with the BamHI and EcoRI digested product of the plpB coding sequence. The PCR product was then expressed under a tac promoter in the plasmid pGEX-5X-1. Finally, the recombinant plasmid was transformed into competent cells of E. coli DH5 expression host by the heat shock method. The recombinant clones were selected on LB agar containing ampicillin (100 g/ml).
Expression and purification of recombinant protein: Positive clones were grown in LB broth in the presence of ampicillin to mid-log phase, and induced with a final concentration of 1 mM IPTG for 3 hr before harvesting the cells. Cells were washed twice with phosphate-buffered saline (PBS) pH 7.4 and resuspended in PBS at 1:20 of the original culture volume. Cells were disrupted using a sonicator and the fusion proteins were purified using GST Purification Module according to the manufacturer's instruction. Briefly, after cell disrupt by sonication, the cell lysate was purified by using GSTrap FF 1 ml column. The recombinant GST-PlpB protein was digested with Factor Xa (Amersham Biosciences, Sweden). The digestion buffer was composed of appropriate amount of recombinant GST-PlpB protein, 10X Factor Xa cleavage buffer (500 mM Tris-HCl, 1 M NaCl, 10 mM CaCl 2 , pH 7.5), 1 unit of Factor Xa and sterile deionized distilled water in a final volume of 10 l.
The mixture was incubated at room temperature (22-25C) for 2-16 hr. The complete digestion was determined by SDS-PAGE.
Analysis of protein sequence: Protein sequence was analyzed by MALDI-TOF mass spectrometer model reflex V (Bruker Daltonik GmbH). The sample was prepared by dried droplet method. The mass spectra were recorded on a reflector Bruker reflex V delayed extraction MALDI-TOF mass spectrometer equipped with a 2GHz LeCroy digitizer and 337 nm N 2 laser. Instrumental parameters were:positive polarity, acceleration voltage 20kV;IS/2 17 kV;focusing lens voltage 8.90 kV ;extraction delay 400 ns. Typically 100 shots were accumulated from three to five different positions within a sample spot. Protein identifications were obtained using MASCOT (MatrixScience) and by searching for matching peptide mass fingerprints in a protein database.The search criteria used were fixed modification carboxamidomethylation of cysteine,variable modification methionine oxidation and considered the accuracy of the experimental to theoretical pI and molecular weight. Protein scores are significant when P value is smaller than 0.05 (P value is the probability that the observed match is a random event).
Acute toxicity test: Specific pathogen-free ICR female mice (15-20 g), 4 weeks of age, were purchased from the National Laboratory Animal Center, Mahidol University, Nakhon Pathom, Thailand. They were supplied with food and water ad libitum. Animals were housed, handled and treated following the procedures approved by the Institutional Animal Care and Use Committee, Faculty of Pharmacy, Mahidol University (Proof No. PYTR010/2550).
The mice were devided in 4 groups (I, II, III and IV). Groups of 10 mice each, were injected subcutaneous (s.c.) with incomplete Freund's adjuvant (IFA). The injection volume was 0.2 ml, in which contained recombinant GST-PlpB protein equivalent to 50, 100, and 200 g protein (I, II and III). The mice in group IV received 0.2 ml of PBS (negative control). Then, the mice were injected again 2 weeks later with the same dose as the primary injection. Mice were observed for 4 weeks to assess pain, distress, or discomfort and, if considered moribund, were euthanized in accordance with animal ethics requirements.
Determination of LD 50 to Pasteurella multocida: Groups of mice were housed under negative pressure and temperature controlled conditions. The fifty percent lethal dose (LD 50 ) was determined by intraperitoneal (i.p.) injection of P. multocida NIAH DU1551/97 (A:1) and P. multocida NIAH DU1275/27 (A:3,4) that were grown at 37C and then serially diluted ten-fold in phosphate buffer saline. Groups of 5 mice each were injected with 100 l of a serial dilution.
Cell suspension was plated on blood agar and incubated for 16 hr at 37C. Mice which were moribund and deemed incapable to survival were euthanized. Quantitation of colony forming units and resultant mortality from each dilution were used for the generation of LD 50 values.
Study on protective effect of the recombinant GST-PlpB protein:
To determine the protective capacity of the recombinant GST-PlpB protein, mice were immunized subcutaneously with recombinant GST-PlpB protein together with incomplete Freund's adjuvant in comparison with inactivated P. multocida FC Pakchong (A:1). The mice were boosted at 2 weeks following the primary immunization and at 4 weeks after the initial vaccination, they were challenged by intraperitoneally injecting approximately 50x-100x LD 50 of P. multocida. Mice were observed for survival and severe pathological effects of the infection; if considered moribund, they were euthanized in accordance with animal ethics requirements.
RESULTS

Distribution of plpB gene among P. multocida isolates:
The genomic DNA of isolated strains frequently found in Thailand (i.e., strains P. multocida FC-Pakchong serotype A:1, P. multocida NIAH DU1551/97 serotype A:1, and P. multocida NIAH D1275/27 serotype A:3,4) was analyzed by PCR to study the distribution of plpB gene. The primers were designed based on the nucleotide sequence of P. multocida Pm70 plpB gene. PCR amplification targeting plpB gene resulted in a product of approximate 831 bp from the genomes of P. multocida strains among serotype A:1 and A:3,4. The sequence of PCR products were compared to the published sequence of corresponding region of P. multocida Pm70 lipoprotein plpB gene and P. multocida P52 lipoprotein plpB gene serotype B:2 (Fig. 1) . The sequences exhibited 98-99% homology overall. The results indicated that the plpB gene was commonly found in different serotypes of P. multocida suggesting the potential for this molecule to be the universal immunogen for a cross-protective vaccine.
Cloning and expression of the recombinant GST-PlpB protein: Based on the nucleotide sequence of P. multocida Pm70 plpB gene, the plpB gene of P. multocida FCPakchong (A:1) was amplified and cloned into E. coli DH5. The pGEX-5X-1 was chosen as an expression vector for expression of the recombinant GST-tagged protein to facilitate subsequent purification by using GST purification system. The recombinant protein from E. coli DH5 harboring pGEX-5X-1-plpB containing the coding sequences of P. multocida FC-Pakchong (A:1) plpB gene was detected in cell lysates and appeared at about 63 kDa on SDS-PAGE gel (Fig. 2) . The recombinant GST-PlpB protein was collected and further purified by using factor Xa protease. Purified recombinant PlpB protein appeared at about 36 kDa (Fig. 3) . The result from protein sequencing by MALDI-TOF MS revealed that the recombinant protein was the PlpB protein of P. multocida (Fig. 4) . This suggested that the recombinant PlpB protein was successfully produced by E. coli harboring pGEX-5X-1 with plpB gene insert.
Acute toxicity of the recombinant GST-PlpB protein:
The result of acute toxicity of the recombinant GST-PlpB protein in vivo revealed that, none of the mice died when injected with any doses of recombinant proteins (50, 100, and 200 g/mouse) (data not shown). The data in this study showed that recombinant GST-PlpB protein lacked acute toxicity at 200 g, which was the maximum dose used for vaccination.
Mouse vaccination and challenge: To determine the protective capacity of the recombinant GST-PlpB protein, mice were immunized with the recombinant protein and challenged with 50x-100x LD 50 of P. multocida. Incomplete Freund's adjuvant was used as the emulsifying agent. The results showed that the LD 50 titer of P. multocida NIAH DU1551/97 (A:1) was about 9.5  10 Table 1 ). Control mice immunized with PBS alone showed a high rate of mortality (100%). In contrast, mice immunized with inactivated P. multocida FC Pakchong (A:1) were 80% protected from lethal challenge.
The LD 50 titer of P. multocida NIAH DU1275/27 (A:3,4) was about 2.7  10 2 cfu. Protection in mice immunized with 50-200 g of recombinant PlpB protein showed a survival rate of 20-30% against challenged with this strain while mice immunized with inactivated P. multocida FC Pakchong (A:1) were 100% protected from lethal challenge ( Table 1) .
DISCUSSION
The PlpB protein was first purified in 2001 as a 39-kDa outer membrane associated protein that could induce cross protection in turkeys against different P. multocida serotypes [10] . Later, Tobatabai and Zehr identified this protein as the Pasteurella lipoprotein B, PlpB [12] . Recently, Wu and colleagues reported that mice immunized with recombinant PlpB protein were not protected against challenge infection with 30 or 60 CFU of P. multocida X-73 serotype A:1 [14] . However, it was unclear whether or not the derived recombinant PlpB was the same protein as the 39 kDa protein that was cross-protective as described earlier by Rimler and Tobatabai [10, 12] . Tobatabai and Zehr reported that the PlpB protein was a 30-kDa protein that appeared on the SDS gel at 39 kDa [12] . Nevertheless, Wu et al. reported the PlpB protein with molecular mass of only 28 kDa and finally concluded that this PlpB was not the same protein as the reported 39-kDa cross protective protein [14] . This led us to investigate of the immunoprotective capacity of the PlpB protein.
In this study, it was demonstrated that the plpB gene was commonly present in different serotypes of P. multocida with high nucleotide sequence homology. The plpB gene was cloned from P. multocida FC Pakchong serotype A:1 and expressed in E. coli. The purified fusion GST-PlpB protein showed a major band migrating at about 63 kDa on a SDS-PAGE gel. After enzyme cleavage, the recombinant PlpB protein appeared at the estimated size of 36 kDa. The results showed no acute toxicity after subcutaneous injection of this protein into mice at the highest tested concentra-tion. However, this recombinant GST-PlpB protein provided 20-30% protection against P. multocida serotype A:1 and A:3,4 infection.
In this report, the 36-kDa recombinant PlpB protein was demonstrated by nucleotide and protein sequencing to be similar, if not identical, to the 39-kDa protein previously reported. The discrepancy in molecular size appeared on the SDS gel between the 39-kDa PlpB of Tobatabai and Zehr and the 36-kDa PlpB of this study could be explained by the retention of 19 amino acids that form the signal sequence at the N-terminus of the 39-kDa form of PlpB protein. Nonetheless, vaccination with the recombinant GST-PlpB protein failed to protect mice against challenge with virulent P. multocida serotype A:1 and A:3,4.
Noteworthy was the report of another 39 kDa capsular protein from P. multocida that appeared to be a cross-pro- tective antigen [1] . The purified 39 kDa capsular protein showed high protection against P. multocida serotype A:1 and A:3 in mice and the recombinant protein also protected chicken from challenge by both serotypes [2, 11] . Although this protein was obtained from a capsular extract and appeared at the same size as the PlpB protein, they were dis- Note: This sequence block (nucleotide 598-825) should come after nucleotide 538. similar proteins. As claimed by Sthitmatee and colleagues this protein has N-terminal sequence similar to the major outer membrane (OmpH) which was reported earlier by Luo et al. [11, 5] . In conclusion, our data indicate that PlpB protein may not be an appropriate target as a candidate subunit vaccine for P. multocida infection. Fig. 3 . SDS-PAGE of putative GST-PlpB fusion protein cleavage with factor Xa. The recombinant GST-PlpB protein was treated with factor Xa for 16 hr at 25C before subjected to SDS-PAGE. 1: Molecular weight standards, low range, 2: factor Xa-cleaved GST-PlpB.
